CN104822826B - 用于蛋白产生的哺乳动物细胞培养过程 - Google Patents

用于蛋白产生的哺乳动物细胞培养过程 Download PDF

Info

Publication number
CN104822826B
CN104822826B CN201380064761.7A CN201380064761A CN104822826B CN 104822826 B CN104822826 B CN 104822826B CN 201380064761 A CN201380064761 A CN 201380064761A CN 104822826 B CN104822826 B CN 104822826B
Authority
CN
China
Prior art keywords
cell
culture
albumen
growth factor
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380064761.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN104822826A (zh
Inventor
田军
M.博里斯
李正剑
N.阿布亚布西
区玉翠
钱南新
戴晓萍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50000068&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104822826(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN104822826A publication Critical patent/CN104822826A/zh
Application granted granted Critical
Publication of CN104822826B publication Critical patent/CN104822826B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/005—Protein-free medium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201380064761.7A 2012-10-15 2013-10-14 用于蛋白产生的哺乳动物细胞培养过程 Expired - Fee Related CN104822826B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261713812P 2012-10-15 2012-10-15
US61/713,812 2012-10-15
US201361888647P 2013-10-09 2013-10-09
US61/888,647 2013-10-09
PCT/US2013/064758 WO2014062535A1 (en) 2012-10-15 2013-10-14 Mammalian cell culture processes for protein production

Publications (2)

Publication Number Publication Date
CN104822826A CN104822826A (zh) 2015-08-05
CN104822826B true CN104822826B (zh) 2019-04-30

Family

ID=50000068

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380064761.7A Expired - Fee Related CN104822826B (zh) 2012-10-15 2013-10-14 用于蛋白产生的哺乳动物细胞培养过程

Country Status (5)

Country Link
EP (1) EP2906683B1 (enExample)
JP (1) JP2015531244A (enExample)
CN (1) CN104822826B (enExample)
ES (1) ES2633960T3 (enExample)
WO (1) WO2014062535A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015531244A (ja) 2012-10-15 2015-11-02 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ タンパク質を製造するための哺乳動物細胞培養方法
WO2017083224A1 (en) * 2015-11-09 2017-05-18 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
AU2017206012A1 (en) * 2016-01-06 2018-07-26 Outlook Therapeutics, Inc. Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition
CN109563161A (zh) 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
SG11202003354VA (en) * 2017-10-13 2020-05-28 Boehringer Ingelheim Int Perfusion medium

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357422A (en) 1980-08-14 1982-11-02 Massachusetts Institute Of Technology Method of enhancing interferon production
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8924021D0 (en) 1989-10-25 1989-12-13 Celltech Ltd Recombinant dna method and vectors for the use therein
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
DE4313620A1 (de) 1993-04-26 1994-10-27 Biotechnolog Forschung Gmbh Hamsterzellinien und Verfahren zur Glykoproteingewinnung
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US5851800A (en) 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
EP2243827B2 (en) 1996-08-30 2017-11-22 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
ES2255765T3 (es) 1998-05-29 2006-07-01 Genentech, Inc. Procedimiento de cultivo de celulas para la produccion de glicoproteinas.
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
ATE348173T1 (de) 1999-04-26 2007-01-15 Genentech Inc Zellenzuchtverfahren für glycoproteine
US6413744B1 (en) 1999-08-25 2002-07-02 Immunex Corporation Methods and host cells for improved cell culture
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
WO2003046162A2 (en) 2001-11-28 2003-06-05 Polymun Scientific Immunbiologische Forschung Gmbh Process for the production of polypeptides in mammalian cell cultures
EP1578928B1 (en) 2002-09-16 2010-03-17 The Johns Hopkins University Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US7332303B2 (en) 2002-12-23 2008-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
AU2003300276B2 (en) 2002-12-23 2010-07-01 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
SI2522717T1 (sl) 2006-01-04 2014-05-30 Baxter International Inc. Mediji celične kulture brez oligopeptidov
WO2008141207A1 (en) * 2007-05-11 2008-11-20 Amgen Inc. Improved feed media
DK2250251T3 (en) 2008-01-09 2018-01-22 Sartorius Stedim Cellca Gmbh Improved culture medium additive and method of using it
KR101574056B1 (ko) 2009-07-31 2015-12-02 백스터 인터내셔널 인코포레이티드 Ａｄａｍｔｓ 단백질 발현을 위한 세포 배양 배지
CA2795461C (en) 2010-04-26 2018-04-24 Novartis Ag Improved cell cultivation process
BR112012027434B1 (pt) 2010-04-26 2020-09-29 Novartis Ag Processo para produção de um polipeptídeo recombinante compreendendo uma fase de produção
US8678606B2 (en) 2010-06-14 2014-03-25 Aja Berger Carrying container with at least two light sources
WO2012023085A1 (en) * 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
JP2015531244A (ja) 2012-10-15 2015-11-02 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ タンパク質を製造するための哺乳動物細胞培養方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Growth factor withdrawal in combination with sodium butyrate addition extends culture longevity and enhances antibody production in CHO cells;Jong Kwang Hong，et al;《Journal of Biotechnology》;20110623;第155卷;225－231 *

Also Published As

Publication number Publication date
ES2633960T3 (es) 2017-09-26
JP2015531244A (ja) 2015-11-02
EP2906683A1 (en) 2015-08-19
EP2906683B1 (en) 2017-05-31
CN104822826A (zh) 2015-08-05
WO2014062535A1 (en) 2014-04-24

Similar Documents

Publication Publication Date Title
CN100402660C (zh) 用于蛋白质生产的哺乳动物细胞培养方法中产物质量提高
KR101402634B1 (ko) 항-노화 화합물을 이용한 단백질 제조 방법
Birch et al. Antibody production
Zhang Mammalian cell culture for biopharmaceutical production
CN101857851A (zh) 用于蛋白质生产的哺乳动物细胞培养方法
MX2012012525A (es) Medio de cultivo mejorado.
EP2906683B1 (en) Mammalian cell culture processes for protein production
CN102498212B (zh) Cho/cert细胞系
US20230323287A1 (en) Overexpression of insulin-like growth factor receptor mutants to modulate igf supplementation
US20170327558A1 (en) Mammalian cell culture processes for protein production
US20230082811A1 (en) Adaptation of platform hosts to igf- media
HK1120552B (en) Methods of protein production using anti-senescence compounds

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190430

CF01 Termination of patent right due to non-payment of annual fee